Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Integrum Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Integrum hat ein Gesamteigenkapital von SEK142.9M und eine Gesamtverschuldung von SEK0.0, wodurch sich der Verschuldungsgrad auf 0% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen SEK165.0M bzw. SEK22.1M. Integrum Das EBIT des Unternehmens beträgt SEK6.5M, so dass der Zinsdeckungsgrad 11.6 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von SEK16.9M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

kr0

Verschuldung

Zinsdeckungsgrad	1.5x
Bargeld	kr16.90m
Eigenkapital	kr142.93m
Gesamtverbindlichkeiten	kr22.07m
Gesamtvermögen	kr165.00m

Jüngste Berichte zur Finanzlage

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

May 03

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: INTEG BDie kurzfristigen Aktiva des Unternehmens (SEK84.0M) übersteigen seine kurzfristigen Passiva (SEK20.5M).

Langfristige Verbindlichkeiten: INTEG BDie kurzfristigen Vermögenswerte des Unternehmens (SEK84.0M) übersteigen seine langfristigen Verbindlichkeiten (SEK5.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: INTEG B ist schuldenfrei.

Schulden abbauen: INTEG B hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 6.6% betrug.

Schuldendeckung: INTEG B hat keine Schulden und muss daher nicht durch den operativen Cashflow gedeckt werden.

Zinsdeckung: INTEG B hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Integrum Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Recent updates

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Price target increased by 7.3% to kr77.25

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

Consensus revenue estimates decrease by 12%

Price target decreased by 31% to kr72.00

New minor risk - Share price stability

Full year 2023 earnings: Revenues miss analyst expectations

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Consensus revenue estimates decrease by 40%

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Consensus forecasts updated

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Does Integrum (STO:INTEG B) Deserve A Spot On Your Watchlist?

First quarter 2023 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q2, 2023 Results on Dec 05, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Price target decreased to kr100.00

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Owner & Chairman exercised options to buy kr1.4m worth of stock.

Investor sentiment improved over the past week

Integrum's (STO:INTEG B) Earnings Aren't As Good As They Appear

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

First quarter 2022 earnings released

Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)

Introducing Integrum (STO:INTEG B), The Stock That Soared 873% In The Last Year

Art Clinic, Center of Excellence in the Nordic countries, has treated its first patient with Integrum's OPRA™ Implant System

Third quarter 2021 earnings released

BG Klinik Tübingen to Treat Thumb Amputees with Integrum's OPRA Implant System

Integrum AB Collaboration with Onkos Pave the Way for Further Growth in the US

New 90-day high: kr56.40